Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.
Arroz M et al. Cytometry B Clin Cytom. 2015 Jan 23. doi: 10.1002/cyto.b.21228. [Epub ahead of print].
Multiple myeloma.
Mehta A. Hematology. 2015 Jan;20(1):58-9. doi: 10.1179/1024533214Z.000000000333.
Minimal residual disease in multiple myeloma: bringing the bench to the bedside.
Mailankody S et al. Nat Rev Clin Oncol. 2015 Jan 27. doi: 10.1038/nrclinonc.2014.239. [Epub ahead of print
CyBorD induction therapy in clinical practice.
Areethamsirikul N et al. Bone Marrow Transplant. 2015 Jan 19. doi: 10.1038/bmt.2014.288. [Epub ahead of print].
How I treat relapsed myeloma.
Bladé J et al. Blood. 2015 Jan 13. pii: blood-2014-10-551531. [Epub ahead of print].
Farm characteristics, allergy symptoms, and risk of non-Hodgkin lymphoid neoplasms in the Agricultural Health Study.
Hofmann JN et al. Cancer Epidemiol Biomarkers Prev. 2015 Jan 12. pii: cebp.1246.2014. [Epub ahead of print].
Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Quach H et al. Intern Med J. 2015 Jan;45(1):94-105. doi: 10.1111/imj.12640.
Multiple myeloma: is a shift toward continuous therapy needed to move forward?
Guglielmelli T et al. Expert Rev Hematol. 2015 Jan 12:1-4. [Epub ahead of print].
Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis.
Kim MG et al. Bone Marrow Transplant. 2015 Jan 12. doi: 10.1038/bmt.2014.297. [Epub ahead of print].
An international ecological study of adult height in relation to cancer incidence for 24 anatomical sites.
Jiang Y et al. Cancer Causes Control. 2015 Jan 10. [Epub ahead of print].
Future distribution of multiple myeloma in the United States by sex, age, and race/ethnicity.
Rosenberg PS et al. Blood. 2015 Jan 8;125(2):410-2. doi: 10.1182/blood-2014-10-609461.
Quality of life in multiple myeloma: clinical validation of the Mexican-Spanish version of the QLQ-MY20 instrument.
Espinoza-Zamora JR et al. Ann Hematol. 2015 Jan 8. [Epub ahead of print].
Do lymphocytes count in myeloma? – are we absolutely sure.
Tadmor T. Leuk Lymphoma. 2015 Jan 7:1-6. [Epub ahead of print].
Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database.
Holmström MO et al. Am J Hematol. 2015 Jan 5. doi: 10.1002/ajh.23932. [Epub ahead of print].
Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma.
Costa LJ et al. Biol Blood Marrow Transplant. 2014 Dec 30. pii: S1083-8791(14)01468-2. doi: 10.1016/j.bbmt.2014.12.024. [Epub ahead of print].
Clinical use of proteasome inhibitors in the treatment of multiple myeloma.
Merin NM et al. Pharmaceuticals (Basel). 2014 Dec 24;8(1):1-20. doi: 10.3390/ph8010001.
Multiple myeloma.
Röllig C et al. Lancet. 2014 Dec 22. pii: S0140-6736(14)60493-1. doi: 10.1016/S0140-6736(14)60493-1. [Epub ahead of print].
Primary hyperparathyroidism and multiple myeloma complicated by Fanconi syndrome: A fortuitous association?
Deroux A et al. Presse Med. 2014 Dec 22. pii: S0755-4982(14)00569-7. doi: 10.1016/j.lpm.2014.08.014. [Epub ahead of print].
A Pooled Analysis of Cigarette Smoking and Risk of Multiple Myeloma from the International Multiple Myeloma Consortium.
Andreotti G et al. Cancer Epidemiol Biomarkers Prev. 2014 Dec 23. pii: cebp.1145.2014. [Epub ahead of print].
Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide.
Alessio V et al. Leuk Lymphoma. 2014 Dec 23:1-21. [Epub ahead of print].
Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-hodgkin lymphoma.
Costa LJ et al. Cancer Control. 2015 Jan;22(1):87-94.